We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
- Authors
Garland, Linda L; Rankin, Cathryn; Gandara, David R; Rivkin, Saul E; Scott, Katherine M; Nagle, Raymond B; Klein-Szanto, Andres J P; Testa, Joseph R; Altomare, Deborah A; Borden, Ernest C
- Abstract
Malignant pleural mesothelioma (MPM) expresses high levels of epidermal growth factor receptor (EGFR), and preclinical studies have identified antitumor activity of EGFR tyrosine kinase inhibitors (TKIs) in MPM. We conducted a phase II trial of the EGFR TKI erlotinib in previously untreated patients with MPM.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 17, p2406
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2006.09.7634